FDA
-
-
-
-
-
-
-
Viking Therapeutics presents obesity drug trial results at conference
-
-
-
-
-
-
-
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Viking Therapeutics presents VK2735 obesity data at ObesityWeek 2025
-
-
-
-
-
-
-
Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
-
-
-
-
-
-
-
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
-
-
-
-
-
-
-
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
-
-
-
-
-
-
-
Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
328,335 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

